Item 7.01 Regulation FD Disclosure.

On January 13, 2020, Microbot Medical Inc. (the "Company") posted presentation materials, including a video, on its website with respect to its recently announced reveal of LIBERTYTM, the world's first fully disposable robotic system for use in neurovascular, cardiovascular and peripheral vascular procedures. The LIBERTY robotic system features a unique compact design with the capability to be operated remotely, reduce radiation exposure and physical strain to the physician, as well as the potential to eliminate the use of multiple consumables through its "One & Done" capabilities. Based on the Company's current regulatory analysis, it anticipates FDA submission with respect to the LIBERTY robotic system within 24 months.

The Company is publicly displaying and demonstrating LIBERTY to investors, journalists and healthcare industry leaders on Monday, January 13, 2020, in San Francisco, California.

The presentation materials can be accessed via the 'Investors' section, under 'Presentations and Resources' of the Registrant's website at www.microbotmedical.com. The Registrant is not undertaking to update these presentations.

The presentation furnished as Exhibit 99.1 to this Current Report on Form 8-K is incorporated herein by reference. The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information herein (including Exhibit 99.1).

© Edgar Online, source Glimpses